Posting of Circular and Notice of General Meeting

RNS Number : 8896Y

Futura Medical PLC

17 May 2021

 

17 May 2021

Futura Medical plc

("Futura" or the "Company")

Posting of Circular and Notice of General Meeting

Further to the Company's announcement of 17 May 2021, that it has conditionally raised £12 million before fees and expenses by way of a Placing and Retail Offer with certain existing institutional and other investors, Futura confirms that the Circular (containing a notice convening the General Meeting) has been posted to Shareholders and will shortly be available for download on the Company's website: https://www.futuramedical.com

Comple tion of the Fundraising is conditional, inter alia, upon Shareholder approval of the Resolutions to be proposed at a general meeting of the Company, expected to be held at the offices of Futura Medical plc at Surrey Technology Centre, 40 Occam Road, Guildford, Surrey GU2 7YG at 10:00 a.m. on 2 June 2021.

The ongoing Government restrictions on mass gatherings, non-essential travel and social contact in relation to COVID are likely to impact the ability of Shareholders to attend the General Meeting. Based on current restrictions, the Board has concluded that it is appropriate to strongly urge shareholders not to attend the General Meeting in person this year. Shareholders are instead requested to make use of the electronic facilities detailed below and to vote remotely.

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: [e-mail]

Tel: [phone]

www.futuramedical.com

Nominated Adviser and Sole Broker:

Liberum

Richard Lindley/ Euan Brown/ Kane Collings

Tel: [phone]

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: [e-mail]

Tel: [phone]

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.  

MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction (ED) through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED.  MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application. MED3000 is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.  www.futuramedical.com

 

END

 

 

MSCGZGMKDNNGMZM